Altimmune’s dual-hormone bet enters Phase 3 trial

Pemvidutide’s balanced glucagon/GLP-1 action heads into pivotal MASH trial, testing if hitting two receptors evenly beats mono-agonist crowd. Altimmune has dosed its first patients in PERFORMA, the Phase 3 trial for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) [1]. It’s a milestone moment for a drug that has spent years positioning itself as something other than […] The post Altimmune’s dual-hormone bet enters Phase 3 trial appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.